Note 3 - Revenue |
12 Months Ended |
---|---|
Dec. 31, 2023 | |
Notes to Financial Statements | |
Revenue from Contract with Customer [Text Block] |
3. Revenue
On February 2, 2022, the Company announced an addendum to the 2019 Janssen Manufacturing Agreement XBiotech continued to manufacture Bermekimab for use by Janssen in its clinical trials through November 2022. For the year ended December 31, 2022, the Company recorded $4.0 million of revenues, under the February 2022 agreement. The agreement was terminated in November 2022. |